Drug Research
USPTO issues notice of allowance for GW Pharmaceuticals Sativex formulation spray device
The USPTO has issued a notice of allowance for GW Pharmaceuticals' patent application regarding Sativex formulation spray device. The patent alleges a metered valve pump spray device comprising a liquid cannabis extract, in propylene...
Drug Research
Nuvo Research announces launch of Pliaglis in Europe
Specialty pharmaceutical company Nuvo Research has announced the launch of Pliaglis (lidocaine and tetracaine) cream 7%/7% by Galderma in Europe. Galderma has worldwide marketing rights for Nuvo's Pliaglis, a topical local anesthetic cream indicated...
Drug Research
UK, India sign deal to support R&D, innovation projects
The Technology Strategy Board (TSB) in the UK and the Indian government's Department of Science and Technology have signed 'Programme of Co-operation' deal to support joint, collaborative research and development (R&D) and innovation projects in key areas, including...
Drug Research
ImmBio gets Biomedical Catalyst support to develop pneumococcal vaccine PnuBioVax
Immunobiology (ImmBio), a UK-based biopharmaceutical company, has bagged £0.2m in funding from the UK government-backed Biomedical Catalyst (BBC) for the pre-clinical development of pneumococcal vaccine PnuBioVax. The pharma company had also received £1m from...
Drug Research
Merck, Luminex collaborate to develop companion diagnostic device
Merck, referred to as MSD outside the US and Canada, and Luminex have signed a deal to develop a companion diagnostic device to support patient selection for the clinical development program of investigational drug MK-8931 to treat Alzheimer's...
Drug Research
Mylan Pharmaceuticals launches Fenofibrate Capsules
Mylan Pharmaceuticals, a subsidiary of global pharmaceutical company Mylan, has launched Fenofibrate Capsules USP, 43 mg and 130 mg. Fenofibrate Capsules, which are generic equivalent to Lupin Atlantis Holdings' Antara Capsules, are indicated as...
Drug Research
UCB, ConfometRx sign drug discovery research deal
Belgium-based biopharmaceutical company UCB has signed a research deal with ConfometRx for the discovery of new drugs. Under the deal, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
